Novartis: positive phase III data for Lutathera

(CercleFinance.com) - Novartis announces that the Phase III NETTER-2 trial evaluating Lutathera in the first-line treatment of advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) has met its primary endpoint.


Combined with long-acting octreotide, it demonstrated a significant improvement in progression-free survival in newly diagnosed patients, compared with high-dose long-acting octreotide alone.

Lutathera also met the key secondary endpoint of objective response rate. No new or unexpected safety findings were observed in the study, and the data are consistent with its already well-established safety profile.

Lutathera is the first radioligand therapy to demonstrate a clinically meaningful benefit in a first-line setting, Novartis says, which will discuss these results with regulatory authorities.


Copyright (c) 2023 CercleFinance.com. All rights reserved.